Literature DB >> 25217719

Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities.

Nicola Micale1, Tanja Schirmeister2, Roberta Ettari3, Maria A Cinellu4, Laura Maiore5, Maria Serratrice4, Chiara Gabbiani6, Lara Massai7, Luigi Messori8.   

Abstract

Six structurally diverse cytotoxic gold compounds are reported to cause profound and differential inhibition of the three main catalytic activities of purified 20S proteasome whilst auranofin, an established gold(I) drug in clinical use, is nearly ineffective. In particular, the gold(I) complex [(pbiH)Au(PPh3)]PF6, turns out to be the most potent inhibitor of all three enzyme activities with sub-micromolar IC50 values. The present results further support the view that proteasome inhibition may play a major--yet not exclusive--role in the cytotoxic actions of gold based anticancer agents.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Enzyme inhibition; Gold compounds; Proteasome

Mesh:

Substances:

Year:  2014        PMID: 25217719     DOI: 10.1016/j.jinorgbio.2014.08.001

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  6 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer.

Authors:  Tiziano Marzo; Lara Massai; Alessandro Pratesi; Matteo Stefanini; Damiano Cirri; Francesca Magherini; Matteo Becatti; Ida Landini; Stefania Nobili; Enrico Mini; Olivia Crociani; Annarosa Arcangeli; Serena Pillozzi; Tania Gamberi; Luigi Messori
Journal:  ACS Med Chem Lett       Date:  2019-02-07       Impact factor: 4.345

3.  Selection and characterization of a human ovarian cancer cell line resistant to auranofin.

Authors:  Luigi Messori; Enrico Mini; Stefania Nobili; Ida Landini; Andrea Lapucci; Alessandro Pratesi; Lara Massai; Cristina Napoli; Gabriele Perrone; Pamela Pinzani
Journal:  Oncotarget       Date:  2017-10-09

4.  Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study.

Authors:  Iogann Tolbatov; Damiano Cirri; Lorella Marchetti; Alessandro Marrone; Cecilia Coletti; Nazzareno Re; Diego La Mendola; Luigi Messori; Tiziano Marzo; Chiara Gabbiani; Alessandro Pratesi
Journal:  Front Chem       Date:  2020-09-18       Impact factor: 5.221

5.  Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System.

Authors:  Damiano Cirri; Tanja Schirmeister; Ean-Jeong Seo; Thomas Efferth; Lara Massai; Luigi Messori; Nicola Micale
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411

6.  Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles.

Authors:  Serena Pillozzi; Damiano Cirri; Alessio Menconi; Tiziano Marzo; Lara Massai; Alessandro Pratesi; Mirko Severi; Giulia Petroni; Lorenzo Antonuzzo; Luigi Messori
Journal:  Biometals       Date:  2021-04-27       Impact factor: 2.949

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.